Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. How Involvement in Research Can Help Develop Your Career
  2. Frontline ICI-Based Combination Therapy in Patients With Metastatic RCC With Poor Performance Status
  3. Perioperative Morbidity Associated With Metastasectomy in Patients With Renal Cell Carcinoma
  4. 2022 Top Story in Renal Cell Carcinoma: Triplet Combination Therapy for Advanced RCC
  5. Safety of Concurrent Radiotherapy and Cabozantinib Use for Treating Patients With Metastatic RCC
  6. Surgical Management and Oncologic Outcomes for Local Retroperitoneal Recurrence of RCC After Radical Nephrectomy
  7. Efficacy and Safety of Nivolumab Plus Ipilimumab in the Second-Line Setting in Advanced RCC
  8. Safety of Concurrent Use of Cabozantinib With Direct Oral Anticoagulants in Patients With mRCC
  9. Nivolumab Plus Ipilimumab Plus Cabozantinib Triplet Combination for Patients With Previously Untreated Advanced RCC
  10. PFS After Second-Line Therapy in Patients With Metastatic ccRCC Treated With First-Line Immunotherapy Combinations

Elsewhere

Recently Updated